Validation process Cycle development

As we know, a critical step within the development cycle of any new product or process is the scale-up step. At this particular point, it is very important that adequate communications have occurred between the group responsible for the product development and the group charged with process validation. Actually, in many organizations, the process/product development department shoulders the responsibility for product scale-up and then transfers the technology to manufacturing for product commercialization [6],... 

Hokanson, G. C. A life cycle approach to the validation of analytical methods during pharmaceutical product development, part I The initial validation process. Pharm Tech 118-130 (Sept. 1994). 

The following section discusses the three main steps of the biomarker validation process, or the fife cycle of a biomarker (1) its identification and development, (2) its validation using epidemiological methods, and (3) its application in etiological or clinical studies. 

The steps in the validation life cycle are not necessarily executed in the order indicated. Rather, the steps are usually executed as an iterative process in which various functions may be carried out concurrently. If necessary, steps may be repeated. For instance, the Validation Master Plan may be developed after, or concurrently with, the User Requirements Specification (URS) rather than before, as indicated. Equally, a Supplier Audit often involves a series of steps that may not be complete until well into the validation project. 

The validation activities within the validation life cycle should be carried out according to the scheme shown in Figure 1.1. The documentation of the validation process is carried out in the form of programs that must be developed by the qualihcation/validation teams. These programs must be approved by the review team. After approval, the validation activities can start and a report of the activities must be produced. The approval of this report must be given by the same people who approved the program. 

Validation of computerized systems differs from the validation processes previously described because of the complexity and key-function in the process controls of such systems. Therefore, computer validation has a special life cycle (system development life cycle [SDLC]) that contains the hardware and the software. The sub-sections of the SDLC are similar to the subsections of the life cycles for prospective/retrospective validation processes. 

The washing of components will be validated for each load configuration in the vial washer. Cycle Development Testing and Performance Qualification testing will qualify each washing process. A separate performance qualification and cycle development testing report will be written for each load configuration. The processes will be considered validated when the acceptance criteria is met for three (3) successful consecutive runs. 

Enhanced turn-over package Installation qualification protocols Operational qualification protocols Change control initiation Cycle development Performance qualification protocol Process validation protocols Validation final reports Validation package Certificate for use in manufacturing Required protocols and procedures for dry production Required protocols and procedures for liquid and semisolid products... 

Fig. 16-1 From target identification to optimization process is performed in cycles, candidate drug (CD). Target identification and at the end of the lead optimization and validation are followed by lead discovery process the developability of the and lead optimization. The lead compounds is traditionally investigated.

Both approaches require some estimation of product bioburden. It is not advisable for ethylene oxide sterilization processes to be validated without at least some estimates of numbers of product contaminants. This is irrespective of whether cycle development is by the so-called overkill or the so-called bio-burden method (see below). 

The primary focus in the analytical considerations of immunoassays for macromolecules should be in the development phase. By thoroughly defining each component of the immunoassay in the first phase of the assay life cycle, the resulting validation plan should be concise and the validation process should be straightforward. Several facets of the assay defined in the late development stage, such as specificity and dilutional linearity, can appropriately be included in the final validation report. 

Determination of the useful lifetime of a resin occupies much effort in any process development program. In fact, because of validation considerations, it is perhaps the major cost factor. A very useful model has been presented for determining the number of cycles for which a given resin can be used.59 This program involves activities in six main areas ... 

---